Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter Open-Label Extension Study of Faricimab in nAMD
2020-004523-16Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of faricimab in exudative macular degeneration and age-related macular degeneration (AMD), sponsored by Roche. Primary endpoint: Incidence and severity of ocular adverse events. Started Mar 2021; status: completed.
02
Drugs
faricimab
03
Conditions
exudative macular degenerationage-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2020-004523-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004523-16.